References
  1. Picard N, Yee SW, Woillard JB, Lebranchu Y, Le Meur Y, Giacomini KM, Marquet P. The role of organic antion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharm Ther 2010; 87:100-108.
  2. Boumar R, Hessenlink DA, van Schaik RHN, Weimar W, van der Heiden I, de Fijter JW et al. Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. Pharmacogen Genom 2012; 22:399-407.
  3. Geng F, Jiao Z, Dao YJ, Qiu XY, Ding JJ, Shi Xj et al. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic aid and its phenolic glucuronide metabolite in Chinese individuals. Clinic Chimica Acta 2012; 423:683-690.
  4. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007; 63:1161-1169.
  5. van Schaik RHN, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K et al. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 2009; 86:319-327.
  6. Kuypers DR, Naesens M, Vermeire S, Vanrentghem Y. The impact of uridine diphosphate-glucuronosyltrasferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005; 78:351-361.
  7. Baldelli S, Merlini S, Perico N, Nicastri A, Cortinovis M et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 2007;8:1127-1141.
  8. Michelon H, Konig J, Durrbach A, Quteineh L, Cerstuyft C, Furlan V et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 2010; 11:1703-1713.
  9. Woillard JB, Picard N, Thierry A, Touchard G, Marquet P. Associations between polymorphisms in target, metabolism or transport proteins of mycophenenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenet Genomics 2014; 24:256-262.
  10. Zhao W, Fakhoury M, Deschenes G, Roussey G, Brochard K, Niaudet P et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal transplant patients. J Clin Pharmacol 2010; 50:1280-1291.
  11. Pazik J, Oldak M, Dabrowski M, Lewandowski Z, Sitarek E, Podgorska M et al. Association of udp-glucuronosyltransferase 1A9 (UGT1A9) gene polymorphism with kindey allograft function. Ann Transplant 2011; 16:69-73.
  12. Pazik J, Oldak M, Lewandowski Z, Dabrowski M, Podgorska M, Sitarek E et al. Recipient uridine 5’-diphospho-glucuronosyltransferase UGT1A9 c.98T>C variant determines transplanted kidney filtration rate. Transplant Proceedings 2014; 46:2678-2682.